| Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ A Noto, C De Vitis, ME Pisanu, G Roscilli, G Ricci, A Catizone, ... Oncogene 36 (32), 4573-4584, 2017 | 184 | 2017 |
| Structural features of subtype-selective EP receptor modulators T Markovič, Ž Jakopin, MS Dolenc, I Mlinarič-Raščan Drug discovery today 22 (1), 57-71, 2017 | 173 | 2017 |
| Xanthine oxidase inhibitors beyond allopurinol and febuxostat; an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted … A Šmelcerović, K Tomović, Ž Šmelcerović, Ž Petronijević, G Kocić, ... European journal of medicinal chemistry 135, 491-516, 2017 | 122 | 2017 |
| Blockade of Stearoyl-CoA-desaturase 1 activity reverts resistance to cisplatin in lung cancer stem cells ME Pisanu, A Noto, C De Vitis, S Morrone, G Scognamiglio, G Botti, ... Cancer letters 406, 93-104, 2017 | 120 | 2017 |
| Recent Advances in the Synthesis of 1, 2, 4-and 1, 3, 4-Oxadiazoles Z Jakopin, MS Dolenc Current organic chemistry 12 (10), 850-898, 2008 | 98 | 2008 |
| Modulation of immune responses using adjuvants to facilitate therapeutic vaccination V Schijns, A Fernández‐Tejada, Ž Barjaktarović, I Bouzalas, J Brimnes, ... Immunological reviews 296 (1), 169-190, 2020 | 78 | 2020 |
| Ferritin heavy chain is a negative regulator of ovarian cancer stem cell expansion and epithelial to mesenchymal transition N Lobello, F Biamonte, ME Pisanu, MC Faniello, Ž Jakopin, E Chiarella, ... Oncotarget 7 (38), 62019, 2016 | 78 | 2016 |
| Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma ME Pisanu, M Maugeri-Saccà, L Fattore, S Bruschini, C De Vitis, E Tabbì, ... Journal of Experimental & Clinical Cancer Research 37, 1-17, 2018 | 75 | 2018 |
| Nucleotide-binding oligomerization domain (NOD) inhibitors: a rational approach toward inhibition of NOD signaling pathway Z Jakopin Journal of medicinal chemistry 57 (16), 6897-6918, 2014 | 75 | 2014 |
| 3,4-Dihydro-2H-1,4-benzoxazine Derivatives Combining Thrombin Inhibitory and Glycoprotein IIb/IIIa Receptor Antagonistic Activity as a Novel Class of … J Ilaš, Z Jakopin, T Borštnar, M Stegnar, D Kikelj Journal of medicinal chemistry 51 (18), 5617-5629, 2008 | 69 | 2008 |
| Discovery of substituted oxadiazoles as a novel scaffold for DNA gyrase inhibitors Ž Jakopin, J Ilaš, M Barančoková, M Brvar, P Tammela, MS Dolenc, ... European Journal of Medicinal Chemistry 130, 171-184, 2017 | 67 | 2017 |
| Antioxidant and anti-inflammatory properties of 1, 2, 4-oxadiazole analogs of resveratrol M Gobec, T Tomašič, T Markovič, I Mlinarič-Raščan, MS Dolenc, ... Chemico-Biological Interactions 240, 200-207, 2015 | 63 | 2015 |
| Advances in the chemistry of saccharins: From synthetic novelties towards biologically active compounds Z Jakopin, MS Dolenc Current medicinal chemistry 17 (7), 651-671, 2010 | 48 | 2010 |
| Synthesis of 3, 5-disubstituted 1, 2, 4-oxadiazoles as peptidomimetic building blocks Ž Jakopin, R Roškar, MS Dolenc Tetrahedron letters 48 (8), 1465-1468, 2007 | 46 | 2007 |
| Risks associated with fat burners: a toxicological perspective Ž Jakopin Food and Chemical Toxicology 123, 205-224, 2019 | 44 | 2019 |
| Murabutide revisited: a review of its pleiotropic biological effects Z Jakopin Current medicinal chemistry 20 (16), 2068-2079, 2013 | 43 | 2013 |
| Discovery of nanomolar desmuramylpeptide agonists of the innate immune receptor nucleotide-binding oligomerization domain-containing protein 2 (NOD2) possessing … M Gobec, T Tomašič, A Štimac, R Frkanec, J Trontelj, M Anderluh, ... Journal of medicinal chemistry 61 (7), 2707-2724, 2018 | 41 | 2018 |
| Immunomodulatory properties of novel nucleotide oligomerization domain 2 (Nod2) agonistic desmuramyldipeptides Z Jakopin, M Gobec, I Mlinarič-Raščan, M Sollner Dolenc Journal of medicinal chemistry 55 (14), 6478-6488, 2012 | 40 | 2012 |
| Harnessing the untapped potential of nucleotide‐binding oligomerization domain ligands for cancer immunotherapy S Nabergoj, I Mlinarič‐Raščan, Ž Jakopin Medicinal research reviews 39 (5), 1447-1484, 2019 | 39 | 2019 |
| Structural requirements of acylated Gly-l-Ala-d-Glu analogs for activation of the innate immune receptor NOD2 M Gobec, I Mlinarič-Raščan, MS Dolenc, Ž Jakopin European Journal of Medicinal Chemistry 116, 1-12, 2016 | 34 | 2016 |
